Arsenic modulates APOBEC3G-mediated restriction to HIV-1 infection in myeloid dendritic cells

Area of Science:

• Immunology
• Virology
• Cell Biology

Background:

• Dendritic cells (DC) are primary targets for HIV-1 during early infection, yet exhibit inefficient in vitro infection compared to CD4+ T lymphocytes.
• A cellular restriction factor, APOBEC3G (A3G), imposes a significant post-entry block on HIV-1 replication in myeloid dendritic cells (MDDC).
• Arsenic trioxide (As₂O₃), a drug for acute promyelocytic leukemia, was previously shown to overcome this restriction in both MDDC and blood-derived MyDC, with unclear mechanisms.

Purpose of the Study:

• To investigate the interaction between As₂O₃ and A3G-mediated restriction in primary dendritic cell subsets.
• To elucidate the mechanisms by which As₂O₃ affects HIV-1 restriction in different DC types.

Main Methods:

• Utilized primary human myeloid dendritic cells (MyDC) and myeloid dendritic cells (MDDC).
• Employed RNA interference (RNAi) to specifically deplete A3G in MyDC.
• Assessed HIV-1 infection levels in DC subsets treated with As₂O₃, with and without A3G depletion.

Main Results:

• As₂O₃ effectively counteracted A3G-mediated restriction of HIV-1 infection in MyDC.
• This effect was largely dependent on the presence of A3G, as demonstrated by RNAi experiments in MyDC.
• Conversely, As₂O₃ did not counteract A3G-mediated restriction in MDDC.

Conclusions:

• An unexpected interplay exists between As₂O₃ and A3G-mediated restriction of HIV-1 infection in primary human MyDC.
• The efficacy of As₂O₃ in overcoming HIV-1 restriction is cell-type specific within dendritic cell subsets.
• This study highlights differential mechanisms of viral restriction and drug intervention in distinct immune cell populations.